FR2665360B1 - Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues. - Google Patents

Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues.

Info

Publication number
FR2665360B1
FR2665360B1 FR9109773A FR9109773A FR2665360B1 FR 2665360 B1 FR2665360 B1 FR 2665360B1 FR 9109773 A FR9109773 A FR 9109773A FR 9109773 A FR9109773 A FR 9109773A FR 2665360 B1 FR2665360 B1 FR 2665360B1
Authority
FR
France
Prior art keywords
compositions
preparation
sustained release
release compositions
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9109773A
Other languages
English (en)
French (fr)
Other versions
FR2665360A1 (fr
Inventor
Jean-Marc Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of FR2665360A1 publication Critical patent/FR2665360A1/fr
Application granted granted Critical
Publication of FR2665360B1 publication Critical patent/FR2665360B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9109773A 1990-08-01 1991-08-01 Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues. Expired - Fee Related FR2665360B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909016885A GB9016885D0 (en) 1990-08-01 1990-08-01 Sustained release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
FR2665360A1 FR2665360A1 (fr) 1992-02-07
FR2665360B1 true FR2665360B1 (fr) 1995-02-10

Family

ID=10679993

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9109773A Expired - Fee Related FR2665360B1 (fr) 1990-08-01 1991-08-01 Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues.

Country Status (30)

Country Link
US (1) US5213812A (enExample)
JP (1) JP2818704B2 (enExample)
KR (1) KR920003962A (enExample)
AT (1) AT396425B (enExample)
AU (2) AU649696B2 (enExample)
BE (1) BE1004772A3 (enExample)
CA (1) CA2048270C (enExample)
CH (1) CH682715A5 (enExample)
DE (1) DE4125542A1 (enExample)
DK (1) DK175756B1 (enExample)
ES (1) ES2046083B1 (enExample)
FI (1) FI104149B1 (enExample)
FR (1) FR2665360B1 (enExample)
GB (1) GB9016885D0 (enExample)
GR (1) GR1001512B (enExample)
HK (1) HK33294A (enExample)
IE (1) IE65124B1 (enExample)
IN (1) IN178446B (enExample)
IT (1) IT1251788B (enExample)
LU (1) LU87982A1 (enExample)
MA (1) MA22245A1 (enExample)
MY (1) MY107500A (enExample)
NL (1) NL194637C (enExample)
NO (1) NO300158B1 (enExample)
NZ (1) NZ238981A (enExample)
OA (1) OA09387A (enExample)
PT (1) PT98497B (enExample)
SE (1) SE505734C2 (enExample)
TN (1) TNSN91067A1 (enExample)
ZA (1) ZA915565B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19617137C1 (de) * 1996-04-29 1997-02-27 Henkel Kgaa Verwendung von Copolymerestern für die Herstellung von Mikrosphären

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
WO1995022963A1 (en) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DE19604744A1 (de) 1996-02-09 1997-08-14 Henkel Kgaa Technische Di-/Triglyceridgemische
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
KR100707710B1 (ko) * 1998-12-16 2007-04-18 아벤티스 파마슈티칼스 인크. 생분해가능한 중합체로 캡슐화된 세로토닌 수용체 길항제및 이의 제조방법
AU5644400A (en) * 1999-09-24 2001-03-29 Rohm And Haas Company Pellet compositions
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ATE395042T1 (de) * 2001-08-16 2008-05-15 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
FR2848113B1 (fr) * 2002-12-04 2005-02-25 Oreal Stabilisation de principes actifs aromatiques par des polymeres aromatiques
US20040166077A1 (en) * 2002-12-04 2004-08-26 L'oreal Process for treating keratin materials with aromatic active principles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US20060135277A1 (en) * 2003-09-10 2006-06-22 Marnocha Bendict F Golf club and practice arrangement
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7884085B2 (en) * 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
US20060127486A1 (en) * 2004-07-13 2006-06-15 Moerck Rudi E Ceramic structures for prevention of drug diversion
WO2006017337A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for controlled release of drugs
WO2006050345A1 (en) * 2004-10-29 2006-05-11 Adhesives Research, Inc. Microscopic tagging system for security identification
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
AU2006283170A1 (en) * 2005-08-23 2007-03-01 Altairnano, Inc. Highly photocatalytic phosphorus-doped anatase-TiO2 composition and related manufacturing methods
US20080020175A1 (en) * 2006-03-02 2008-01-24 Fred Ratel Nanostructured Indium-Doped Iron Oxide
US20080044638A1 (en) * 2006-03-02 2008-02-21 Fred Ratel Nanostructured Metal Oxides
WO2007103812A1 (en) * 2006-03-02 2007-09-13 Altairnano, Inc. Method for low temperature production of nano-structured iron oxide coatings
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
CA2942128C (en) 2006-08-04 2019-11-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20080248122A1 (en) * 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2008128000A1 (en) * 2007-04-12 2008-10-23 Altairnano, Inc. Teflon replacements and related production methods
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US9782300B2 (en) 2008-02-01 2017-10-10 Kci Licensing, Inc. Fiber-microsphere bioresorbable composite scaffold for wound healing
WO2009129544A1 (en) 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010132763A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
EP2435094A2 (en) 2009-05-27 2012-04-04 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
WO2011038053A1 (en) * 2009-09-25 2011-03-31 Armark Authentication Technologies, Llc Tissue fiber scaffold and method for making
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
AU2011325857A1 (en) 2010-11-01 2013-05-02 University Of Technology, Sydney Immune-modulating agents and uses therefor
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
ES2936067T3 (es) 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
FR3067226B1 (fr) * 2017-06-13 2021-10-08 Rossignol Lange Element de chaussure de ski

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IN167096B (enExample) * 1985-04-04 1990-09-01 Akzo Nv
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
EP0366058A3 (en) * 1988-10-27 1991-03-20 Abbott Laboratories Controlled-release delivery device, method for producing device, and method of using device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19617137C1 (de) * 1996-04-29 1997-02-27 Henkel Kgaa Verwendung von Copolymerestern für die Herstellung von Mikrosphären

Also Published As

Publication number Publication date
SE9102249L (sv) 1992-02-02
OA09387A (fr) 1992-09-15
MY107500A (en) 1995-12-30
US5213812A (en) 1993-05-25
IN178446B (enExample) 1997-05-03
DE4125542A1 (de) 1992-02-06
NL194637C (nl) 2002-10-04
CH682715A5 (fr) 1993-11-15
NO912986D0 (no) 1991-07-31
AU8146691A (en) 1992-02-06
IE65124B1 (en) 1995-10-04
ES2046083A1 (es) 1994-01-16
MA22245A1 (fr) 1992-04-01
AT396425B (de) 1993-09-27
AU649696B2 (en) 1994-06-02
FI104149B (fi) 1999-11-30
SE505734C2 (sv) 1997-10-06
GB9016885D0 (en) 1990-09-12
GR1001512B (el) 1994-02-28
BE1004772A3 (fr) 1993-01-26
NO300158B1 (no) 1997-04-21
CA2048270A1 (en) 1992-02-02
PT98497B (pt) 1997-10-31
ITMI911953A0 (it) 1991-07-15
PT98497A (pt) 1992-06-30
FI913646A0 (fi) 1991-07-31
NL194637B (nl) 2002-06-03
NO912986L (no) 1992-02-03
ZA915565B (en) 1992-04-29
NL9101306A (nl) 1992-03-02
AU5939394A (en) 1994-06-02
AU666808B2 (en) 1996-02-22
JP2818704B2 (ja) 1998-10-30
ITMI911953A1 (it) 1993-01-15
IT1251788B (it) 1995-05-26
JPH05178740A (ja) 1993-07-20
LU87982A1 (fr) 1992-04-15
DK175756B1 (da) 2005-02-14
DK141891A (da) 1992-02-02
SE9102249D0 (sv) 1991-07-26
CA2048270C (en) 1997-02-25
FI104149B1 (fi) 1999-11-30
KR920003962A (ko) 1992-03-27
NZ238981A (en) 1992-11-25
GR910100330A (en) 1992-08-31
HK33294A (en) 1994-04-22
ES2046083B1 (es) 1994-08-01
DK141891D0 (da) 1991-07-31
ATA152591A (de) 1993-01-15
TNSN91067A1 (fr) 1992-10-25
FI913646L (fi) 1992-02-02
IE912700A1 (en) 1992-02-12
FR2665360A1 (fr) 1992-02-07

Similar Documents

Publication Publication Date Title
FR2665360B1 (fr) Procede de preparation de compositions a liberation prolongee et compositions ainsi obtenues.
FI914174A7 (fi) Menetelmä piperidyylialkyyliamiinien valmistamiseksi
AR244238A1 (es) Proceso para la preparacion de n-alquil polihidroxi aminas.
NO911591D0 (no) Fremgangsmaate for fremstilling av sukrose-6-ester.
NO981800L (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
MA23395A1 (fr) Procede de preparation de nouvelles formulations
NO912346L (no) Fremgangsmaate for fremstilling av aminobenzodiazepiner.
TR199600857A2 (tr) Nikotinamidin hazirlanmasi icin islem.
NO941659L (no) Fremgangsmåte for fremstilling av aluminoksaner
FI920018A7 (fi) Menetelmä 3-eksometyleenikefaamisulfoksidiestereiden valmistamiseksi
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
MX9101544A (es) Procedimiento para la produccion de polifluoroolefinas
FI956058A0 (fi) Menetelmä glutaaridialdehydin valmistamiseksi
NO911778D0 (no) Fremgangsmaate for fremstilling av legeringer inneholdendemg2si.
FI913464A7 (fi) Menetelmä 1-hydroksimetyylipyratsolien valmistamiseksi
NO900009L (no) Fremgangsmaate for fremstilling av aspiringranuler med regulert frigivningseffekt.
NO179101C (no) Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol
FI902417A7 (fi) Menetelmä 3-eksometyleenikefaamisulfoksidiesterien valmistamiseksi
FI923866A7 (fi) Menetelmä 1-hydroksialkyyli-5-nitroimidatsolien valmistamiseksi
FI902590A7 (fi) Menetelmä 2-oksoindoli-1-karboksamidien valmistamiseksi
FI910662A7 (fi) Menetelmä 7-amino-3-metoksimetyyli-kef-3-emi-4-karboksyylihapon valmistamiseksi
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
FI953617A7 (fi) Menetelmä substituoitujen 4-hydroksikumariinien valmistamiseksi
FI940338L (fi) Menetelmä 13alfa-sinnamoyylibakkatiini III:n tai -10-desasetyylibakkatiini III:n valmistamiseksi
EP0643724A4 (en) METHOD FOR PRODUCING 3-CARBONYLANDROSTA-DIEN 17-CARBOXAMIDE DERIVATIVES.

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
CA Change of address
CD Change of name or company name
ST Notification of lapse

Effective date: 20110502